Cowan Elvia, SVP of Finance at Vaxcyte (PCVX), has demonstrated a clear selling bias in recent transactions, with no open-market purchases recorded in the past two years. Since February 2024, Elvia has executed 8 sales totaling $1.79 million, dwarfing the $549,918 in buy activity—all of which occurred prior to March 2024. The transactions reveal concentrated activity in PCVX shares, with notable sales including a $367,084 disposition on March 1, 2024, followed by two additional sales the same day totaling $497,985. More recently, Elvia sold $146,481 worth of shares on March 11, 2026, and executed two additional sales on March 17, 2026, valued at $105,146 combined.
The pattern shows Elvia’s sales are often clustered around specific dates, suggesting planned dispositions rather than sporadic trading. For example, three transactions on March 1, 2024, accounted for over $1 million in proceeds, while December 23, 2025, saw two sales totaling $556,971. The absence of recent buys, coupled with consistent selling—including multiple transactions classified as "M" (merger or acquisition-related) and "F" (tax-related)—indicates a sustained reduction in holdings. While some sales appear tied to corporate actions or tax obligations, the overall trend points to a gradual unwinding of Elvia’s position in PCVX over time.
AI-assisted summary